CAJ | 학술논문

目的评价重组人血小板生成素(rhTPO)治疗肺癌患者化疗后血小板减少的临床疗效和安全性.方法 51例肺癌患者在化疗后出现不同程度的血小板减少,根据其血小板下降程度分为轻度、中度、重度组,均给予rhTPO治疗,同时监测血常规、肝肾功能、凝血功能.结果 51例肺癌患者血小板轻度、中度、重度抑制者分别有24、15和12例,rhTPO持续用药时间分别为(5.3±2.8)、(6.3±3.2)和(5.6±2.8)d,3组间差异无统计学意义(P=0.595).血小板开始恢复时间和血小板减少持续时间,轻度组明显低于中度组与重度组(均P＜0.01);rhTPO治疗后,3组患者血小板恢复最高值和血小板提高最大值差异无统计学意义(均P>0.05);3组外源性血小板输注情况比较,差异有统计学意义(P＜0.01),随着血小板减少程度的加重,外源性血小板输注比例增加.结论 rhTPO可用于治疗肺癌患者化疗后出现的Ⅲ、Ⅳ度血小板减少,不良反应轻微.
목적 평개중조인혈소판생성소(rhTPO)치료폐암환자화료후혈소판감소적림상료효화안전성.방법 51례폐암환자재화료후출현불동정도적혈소판감소,근거기혈소판하강정도분위경도、중도、중도조,균급여rhTPO치료,동시감측혈상규、간신공능、응혈공능.결과 51례폐암환자혈소판경도、중도、중도억제자분별유24、15화12례,rhTPO지속용약시간분별위(5.3±2.8)、(6.3±3.2)화(5.6±2.8)d,3조간차이무통계학의의(P=0.595).혈소판개시회복시간화혈소판감소지속시간,경도조명현저우중도조여중도조(균P＜0.01);rhTPO치료후,3조환자혈소판회복최고치화혈소판제고최대치차이무통계학의의(균P>0.05);3조외원성혈소판수주정황비교,차이유통계학의의(P＜0.01),수착혈소판감소정도적가중,외원성혈소판수주비례증가.결론 rhTPO가용우치료폐암환자화료후출현적Ⅲ、Ⅳ도혈소판감소,불량반응경미.
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO) in treatment for chemotherapy-induced thrombocytopenia in patients with lung cancer. Methods Fifty-one lung cancer patients with platelet count ＜100×109/L after chemotherapy were enrolled into this study. They were divided into three groups: mild, moderate and severe thrombocytopenia groups according to the platelet count, rhTPO was subcutaneously administered at a dosage of 300 μg?kg-1?d-1 until the platelet count ≥100×109/L or absolute value of platelet count ≥50×109/L. Laboratory tests included routine blood count, serum biochemistry, and blood coagulation test. Results The duration of the chemotherapy-induced thrombocytopenia was significantly shorter in the mild group than that in the moderate and severe groups (P＜0.01). After administration of rhTPO, the time of declined platelet count beginning to recover was also significantly shorter in the mild group than that in the moderate and severe groups (P＜0.01). There was a statistically significant difference in platelet transfusion needed among the three groups (P＜0.01). However, no significant difference was found among the three groups in the time of rhTPO treatment (P>0.05) and platelet count improvement (P>0.05). Conclusion Recombinant human thrombopoietin can be effectively and safely administered to deal with grade Ⅲ/Ⅳ chemotherapy-induced thrombocytopenia in lung cancer patients with mild adverse effects.